SHANGHAI – In the midst of a busy news week for CRISPR/Cas9 – a powerful tool that gives cut-and-paste accuracy to gene editing by using adapted immune bacteria – Toolgen Inc. has made advances of its own. The Seoul, South Korea-based company shared encouraging results in Nature Communications in a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo.